Oscar Health (OSCR) EBITDA (2020 - 2026)

Oscar Health (OSCR) has reported EBITDA for 7 consecutive years, with $388.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 268.62% year-over-year to $388.6 million; the trailing twelve-month figure through Jun 2026 stood at $413.8 million (up 323.53% YoY), and the FY2025 full-year result was -$396.4 million, down 313.41% from the prior year.
• EBITDA fell to $388.6 million in Q2 2026 per OSCR's latest filing, from $704.1 million in the prior quarter.
• Across five years, EBITDA topped out at $704.1 million in Q1 2026 and bottomed at -$549.7 million in Q4 2025.
• Historically, EBITDA has averaged -$9.0 million across 5 years, with a median of -$38.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 414.64% in 2024, then tumbled 2753.0% in 2025.
• Over 5 years, EBITDA stood at -$222.5 million in 2022, then tumbled by 59.8% to -$355.5 million in 2023, then jumped by 94.58% to -$19.3 million in 2024, then sank by 2753.0% to -$549.7 million in 2025, then surged by 170.7% to $388.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $388.6 million, $704.1 million, and -$549.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.